Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
暂无分享,去创建一个
Yusuke Nakamura | M. Oka | H. Nagano | T. Fujiwara | M. Shimada | S. Hazama | Y. Umeda | T. Ikemoto | Y. Kawakami | T. Hatori | H. Arima | Michihisa Iida | T. Fujita | N. Suzuki | Hiroaki Tanaka | A. Aruga | H. Iguchi | K. Yoshimatsu | H. Furukawa | Y. Shindo | S. Yoshino | Kazuhiro Uesugi | S. Kanekiyo | T. Ueno | H. Takenouchi | H. Matsui | H. Ishizaki | Yasunobu Koki
[1] Yusuke Nakamura,et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study , 2016, Cancer science.
[2] H. Nagano,et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell‐free DNA in plasma in colorectal cancer , 2016, Cancer science.
[3] J. Rosenblatt,et al. Myeloid‐derived suppressor cells as effectors of immune suppression in cancer , 2016, International journal of cancer.
[4] T. Pawlik,et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[5] M. Yao,et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy , 2016, BioMed Research International.
[6] Shiguang Zhu,et al. Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. , 2016, Immunobiology.
[7] H. Nishikawa,et al. Roles of regulatory T cells in cancer immunity. , 2016, International immunology.
[8] H. Lee,et al. Systemic Chemotherapy in Advanced Pancreatic Cancer , 2016, Gut and liver.
[9] H. Nagano,et al. Combined adjuvants of poly(I:C) plus LAG‐3‐Ig improve antitumor effects of tumor‐specific T cells, preventing their exhaustion , 2016, Cancer science.
[10] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[11] H. Saito,et al. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer , 2016, Surgery Today.
[12] T. Todros,et al. Amniotic mesenchymal cells from pre‐eclamptic placentae maintain immunomodulatory features as healthy controls , 2015, Journal of cellular and molecular medicine.
[13] D. V. Von Hoff,et al. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). , 2016, European journal of cancer.
[14] I. Mercier,et al. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators , 2015, Front. Immunol..
[15] A. Thiel,et al. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression , 2015, Cancer Immunology, Immunotherapy.
[16] B. Zhu,et al. T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.
[17] W. Fang,et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer , 2015, Oncotarget.
[18] Yusuke Nakamura,et al. A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS , 2015, Oncoimmunology.
[19] M. Oka,et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. , 2015, Anticancer research.
[20] Yusuke Nakamura,et al. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. , 2014, Anticancer research.
[21] M. Oka,et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer , 2014, Journal of Translational Medicine.
[22] Peng-jun Zhang,et al. Development of serum parameters panels for the early detection of pancreatic cancer , 2014, International journal of cancer.
[23] Yusuke Nakamura,et al. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) , 2014, Journal of Translational Medicine.
[24] Yusuke Nakamura,et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome , 2014, Journal of Translational Medicine.
[25] Shigemi Matsumoto,et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients , 2014, Cancer medicine.
[26] K. Hirakawa,et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. , 2013, Anticancer research.
[27] A. Sarnaik,et al. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma , 2013, Cancer Immunology, Immunotherapy.
[28] T. Whiteside. Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis? , 2013, Front. Oncol..
[29] Yusuke Nakamura,et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens , 2012, Journal of Translational Medicine.
[30] S. Kitano,et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens , 2012, Journal of Translational Medicine.
[31] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[32] Yusuke Nakamura,et al. Recent advances in active specific cancer vaccine treatment for colorectal cancer. , 2012, Current pharmaceutical biotechnology.
[33] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[34] A. Dalgleish,et al. Biomarkers for the Development of Cancer Vaccines , 2006, Molecular Diagnosis & Therapy.
[35] David Cella,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] K. Okuno,et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. , 2010, Experimental and therapeutic medicine.
[37] S. Sakaguchi,et al. Regulatory T cells in tumor immunity , 2010, International journal of cancer.
[38] Douglas B. Evans,et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.
[39] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Shibuya,et al. Inhibition of Tumor Growth with Antiangiogenic Cancer Vaccine Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 1 , 2006, Clinical Cancer Research.
[41] M. Shibuya,et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. , 2005, Cancer research.
[42] K. Taniuchi,et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. , 2005, Cancer research.
[43] Yusuke Nakamura,et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. , 2005, Cancer research.
[44] T. Tsunoda,et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.
[45] M. Shibuya,et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[48] A. Ullrich,et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.